702P + 767C

702P + 767C is an experimental gene therapy combination consisting of two modified U1 small nuclear RNA (snRNA) expression vectors. Developed by researchers at Peking University, these constructs utilize U1 snRNA-mediated gene interference (U1i) to silence the expression of the human chorionic gonadotropin beta subunit (hCGβ). 702P is engineered to target the polyadenylation signal, while 767C targets the cleavage site within the 3' untranslated region (UTR) of the hCGβ pre-mRNA. By binding to these critical processing sites, the modified U1 snRNAs inhibit proper polyadenylation and maturation of the mRNA, leading to its degradation. This reduction in hCGβ levels has been shown to induce apoptosis and inhibit the growth of hCGβ-secreting tumors, such as cervical cancer and choriocarcinoma, in preclinical models.

Other names

U1-702P + U1-767Cmodified U1 snRNA targeting hCG-beta